MRI-guided stereotactic radiation therapy for hepatocellular carcinoma: a feasible and safe innovative treatment approach.
Hepatocellular carcinoma
Magnetic resonance-guided radiotherapy
Multimodality treatment
Radiotherapy
Stereotactic body radiotherapy
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
16
10
2020
accepted:
22
11
2020
pubmed:
6
1
2021
medline:
8
6
2021
entrez:
5
1
2021
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) in early stages benefits from local ablative treatments such as radiofrequency ablation (RFA) or transarterial chemoembolization (TACE). In this context, radiotherapy (RT) has shown promising results but has not been thoroughly evaluated. Magnetic resonance-guided RT (MRgRT) may represent a paradigm shifting improvement in stereotactic body radiotherapy (SBRT) for liver tumors. We retrospectively evaluated HCC patients treated on a hybrid low-tesla MRgRT unit. A total biologically effective dose (BED) > 100 Gy was delivered in 5 consecutive fractions, respecting the appropriate organs-at-risk constraints. Hybrid MR scans were used for treatment planning and cine MR was used for delivery gating. Patients were followed up for toxicity and treatment-response assessment. Ten patients were enrolled, with a total of 12 lesions. All the lesions were irradiated with no interruptions. Six patients had already performed previous local therapies. Median follow-up after SBRT was 6.5 months (1-25). Two cases of acute toxicity were reported (G ≤ 2 according to CTCAE v4.0). At the time of the analysis, 90% of the population presented local control. Child-Pugh before and after treatment remained unchanged in all but one patient. MRgRT is a feasible and safe option showing favorable toxicity profile for HCC treatment.
Identifiants
pubmed: 33398447
doi: 10.1007/s00432-020-03480-8
pii: 10.1007/s00432-020-03480-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2057-2068Références
Andolino DL, Johnson CS, Maluccio M et al (2011) Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncology*Biology*Physics 81:e447–e453. https://doi.org/10.1016/j.ijrobp.2011.04.011
doi: 10.1016/j.ijrobp.2011.04.011
Bae SH, Kim M-S, Cho CK et al (2013) Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci 28:213–219. https://doi.org/10.3346/jkms.2013.28.2.213
doi: 10.3346/jkms.2013.28.2.213
pubmed: 23400333
pmcid: 3565132
Baumann BC, Wei J, Plastaras JP et al (2018) Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: high rates of local control with low toxicity. Am J Clin Oncol 41:1118–1124. https://doi.org/10.1097/COC.0000000000000435
doi: 10.1097/COC.0000000000000435
pubmed: 29553972
Benedict SH, Yenice KM, Followill D et al (2010) Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 37:4078–4101. https://doi.org/10.1118/1.3438081
doi: 10.1118/1.3438081
pubmed: 20879569
Bertuccio P, Turati F, Carioli G et al (2017) Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 67:302–309. https://doi.org/10.1016/j.jhep.2017.03.011
doi: 10.1016/j.jhep.2017.03.011
pubmed: 28336466
Bibault J-E, Dewas S, Vautravers-Dewas C et al (2013) Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS ONE 8:e77472. https://doi.org/10.1371/journal.pone.0077472
doi: 10.1371/journal.pone.0077472
pubmed: 24147002
pmcid: 3795696
Bohoudi O, Bruynzeel AME, Senan S et al (2017) Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. Radiother Oncol 125:439–444. https://doi.org/10.1016/j.radonc.2017.07.028
doi: 10.1016/j.radonc.2017.07.028
pubmed: 28811038
Boldrini L, Cellini F, Manfrida S et al (2018) Use of indirect target gating in magnetic resonance-guided liver stereotactic body radiotherapy: case report of an oligometastatic patient. Cureus. https://doi.org/10.7759/cureus.2292
doi: 10.7759/cureus.2292
pubmed: 29750133
pmcid: 5943029
Boldrini L, Colloca GF, Villani E et al (2020) Magnetic resonance–guided radiotherapy feasibility in elderly cancer patients: proposal of the MASTER scoring system. Tumori J. https://doi.org/10.1177/0300891620920709
doi: 10.1177/0300891620920709
Boldrini L, Cusumano D, Cellini F et al (2019) Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls. Radiat Oncol. https://doi.org/10.1186/s13014-019-1275-3
doi: 10.1186/s13014-019-1275-3
pubmed: 31167658
pmcid: 6551911
Bujold A, Massey C, Kim J, et al (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://pubmed.ncbi.nlm.nih.gov/23547075/ . Accessed 16 Sep 2020
Cárdenes HR, Price TR, Perkins SM et al (2010) Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 12:218–225. https://doi.org/10.1007/s12094-010-0492-x
doi: 10.1007/s12094-010-0492-x
pubmed: 20231127
Chen S-W, Lin L-C, Kuo Y-C et al (2014) Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. Int J Radiat Oncology*Biology*Physics 88:1041–1047. https://doi.org/10.1016/j.ijrobp.2014.01.017
doi: 10.1016/j.ijrobp.2014.01.017
Culleton S, Jiang H, Haddad CR et al (2014) Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 111:412–417. https://doi.org/10.1016/j.radonc.2014.05.002
doi: 10.1016/j.radonc.2014.05.002
pubmed: 24906626
Cusumano D, Dhont J, Boldrini L et al (2018) Predicting tumour motion during the whole radiotherapy treatment: a systematic approach for thoracic and abdominal lesions based on real time MR. Radiother Oncol 129:456–462. https://doi.org/10.1016/j.radonc.2018.07.025
doi: 10.1016/j.radonc.2018.07.025
pubmed: 30144955
Dewas S, Bibault J-E, Mirabel X et al (2012) Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy. Radiat Oncol 7:166. https://doi.org/10.1186/1748-717X-7-166
doi: 10.1186/1748-717X-7-166
pubmed: 23050794
pmcid: 3494572
El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142:1264-1273.e1. https://doi.org/10.1053/j.gastro.2011.12.061
doi: 10.1053/j.gastro.2011.12.061
pubmed: 22537432
pmcid: 3338949
European Association for the Study of the Liver (2018) Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019
doi: 10.1016/j.jhep.2018.03.019
Feldman AM, Modh A, Glide-Hurst C et al (2019) Real-time magnetic resonance-guided liver stereotactic body radiation therapy: an institutional report using a magnetic resonance-linac system. Cureus. https://doi.org/10.7759/cureus.5774
doi: 10.7759/cureus.5774
pubmed: 31723533
pmcid: 6825488
Gerum S, Heinz C, Belka C et al (2018) Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease. Radiat Oncol 13:100. https://doi.org/10.1186/s13014-018-1048-4
doi: 10.1186/s13014-018-1048-4
pubmed: 29843752
pmcid: 5975506
Goodman KA, Wiegner EA, Maturen KE et al (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:486–493. https://doi.org/10.1016/j.ijrobp.2009.08.020
doi: 10.1016/j.ijrobp.2009.08.020
pubmed: 20350791
Hara K, Takeda A, Tsurugai Y et al (2019) Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis. Hepatology 69:2533–2545. https://doi.org/10.1002/hep.30591
doi: 10.1002/hep.30591
pubmed: 30805950
Hass P, Mohnike K, Kropf S et al (2019) Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies. Brachytherapy 18:823–828. https://doi.org/10.1016/j.brachy.2019.08.003
doi: 10.1016/j.brachy.2019.08.003
pubmed: 31522972
Henke L, Kashani R, Robinson C et al (2018) Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol 126:519–526. https://doi.org/10.1016/j.radonc.2017.11.032
doi: 10.1016/j.radonc.2017.11.032
pubmed: 29277446
Huang W-Y, Jen Y-M, Lee M-S et al (2012) Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 84:355–361. https://doi.org/10.1016/j.ijrobp.2011.11.058
doi: 10.1016/j.ijrobp.2011.11.058
pubmed: 22342300
Huertas A, Baumann A-S, Saunier-Kubs F et al (2015) Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol 115:211–216. https://doi.org/10.1016/j.radonc.2015.04.006
doi: 10.1016/j.radonc.2015.04.006
pubmed: 26028227
Hunt A, Hansen VN, Oelfke U et al (2018) Adaptive radiotherapy enabled by mri guidance. Clin Oncol (R Coll Radiol) 30:711–719. https://doi.org/10.1016/j.clon.2018.08.001
doi: 10.1016/j.clon.2018.08.001
Huo YR, Eslick GD (2015) Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. JAMA Oncol 1:756–765. https://doi.org/10.1001/jamaoncol.2015.2189
doi: 10.1001/jamaoncol.2015.2189
pubmed: 26182200
Jang WI, Kim M-S, Bae SH et al (2013) High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 8:250. https://doi.org/10.1186/1748-717X-8-250
doi: 10.1186/1748-717X-8-250
pubmed: 24160944
pmcid: 4231524
Kang J-K, Kim M-S, Cho CK et al (2012) Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 118:5424–5431. https://doi.org/10.1002/cncr.27533
doi: 10.1002/cncr.27533
Kimura T, Aikata H, Takahashi S et al (2015) Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatol Res 45:378–386. https://doi.org/10.1111/hepr.12359
doi: 10.1111/hepr.12359
pubmed: 24849379
Kinoshita A, Onoda H, Fushiya N et al (2015) Staging systems for hepatocellular carcinoma: current status and future perspectives. World J Hepatol 7:406–424. https://doi.org/10.4254/wjh.v7.i3.406
doi: 10.4254/wjh.v7.i3.406
pubmed: 25848467
pmcid: 4381166
Kong X, Dong Y, Wu J et al (2017) High-biologically effective dose palliative radiotherapy for a tumor thrombus might improve the long-term prognosis of hepatocellular carcinoma: a retrospective study. Radiat Oncol 12:92. https://doi.org/10.1186/s13014-017-0831-y
doi: 10.1186/s13014-017-0831-y
pubmed: 28569169
pmcid: 5452386
Kwon JH, Bae SH, Kim JY et al (2010) Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 10:475. https://doi.org/10.1186/1471-2407-10-475
doi: 10.1186/1471-2407-10-475
pubmed: 20813065
pmcid: 2940809
Lasley FD, Mannina EM, Johnson CS et al (2015) Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1–2 trial of stereotactic body radiation therapy. Pract Radiat Oncol 5:e443–e449. https://doi.org/10.1016/j.prro.2015.02.007
doi: 10.1016/j.prro.2015.02.007
pubmed: 25899219
Liu E, Stenmark MH, Schipper MJ et al (2013) Stereotactic body radiation therapy for primary and metastatic liver tumors. Translat Oncol 6:442. https://doi.org/10.1593/tlo.12448
doi: 10.1593/tlo.12448
Llovet JM, Lencioni R (2020) mRECIST for HCC: performance and novel refinements. J Hepatol 72:288–306. https://doi.org/10.1016/j.jhep.2019.09.026
doi: 10.1016/j.jhep.2019.09.026
pubmed: 31954493
Louis C, Dewas S, Mirabel X et al (2010) Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat 9:479–487. https://doi.org/10.1177/153303461000900506
doi: 10.1177/153303461000900506
pubmed: 20815419
Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology 68:723–750. https://doi.org/10.1002/hep.29913
doi: 10.1002/hep.29913
pubmed: 29624699
Massaccesi M, Cusumano D, Boldrini L et al (2019) A new frontier of image guidance: organs at risk avoidance with mri-guided respiratory-gated intensity modulated radiotherapy: technical note and report of a case. J Appl Clin Med Phys 20:194–198. https://doi.org/10.1002/acm2.12575
doi: 10.1002/acm2.12575
pubmed: 31055870
pmcid: 6560311
Moon DH, Wang AZ, Tepper JE (2018) A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy. Radiother Oncol 126:527–533. https://doi.org/10.1016/j.radonc.2018.01.004
doi: 10.1016/j.radonc.2018.01.004
pubmed: 29366521
Murray LJ, Dawson LA (2017) Advances in stereotactic body radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol 27:247–255. https://doi.org/10.1016/j.semradonc.2017.02.002
doi: 10.1016/j.semradonc.2017.02.002
pubmed: 28577832
Noel CE, Parikh PJ, Spencer CR et al (2015) Comparison of onboard low-field magnetic resonance imaging versus onboard computed tomography for anatomy visualization in radiotherapy. Acta Oncol 54:1474–1482. https://doi.org/10.3109/0284186X.2015.1062541
doi: 10.3109/0284186X.2015.1062541
pubmed: 26206517
Placidi L, Romano A, Chiloiro G et al (2020) On-line adaptive MR guided radiotherapy for locally advanced pancreatic cancer: clinical and dosimetric considerations. Tech Innovat Patient Support Radiat Oncol 15:15–21. https://doi.org/10.1016/j.tipsro.2020.06.001
doi: 10.1016/j.tipsro.2020.06.001
Rosenberg SA, Henke LE, Shaverdian N et al (2019) A Multi-institutional experience of MR-guided liver stereotactic body radiation therapy. Adv Radiat Oncol 4:142–149. https://doi.org/10.1016/j.adro.2018.08.005
doi: 10.1016/j.adro.2018.08.005
pubmed: 30706022
Sanuki N, Takeda A, Oku Y et al (2014) Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncologica 53:399–404. https://doi.org/10.3109/0284186X.2013.820342
doi: 10.3109/0284186X.2013.820342
pubmed: 23962244
Schefter TE, Kavanagh BD, Timmerman RD et al (2005) A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 62:1371–1378. https://doi.org/10.1016/j.ijrobp.2005.01.002
doi: 10.1016/j.ijrobp.2005.01.002
pubmed: 16029795
Scorsetti M, Comito T, Cozzi L et al (2015) The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol 141:1301–1309. https://doi.org/10.1007/s00432-015-1929-y
doi: 10.1007/s00432-015-1929-y
pubmed: 25644863
Seo YS, Kim M-S, Yoo SY et al (2010) Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 102:209–214. https://doi.org/10.1002/jso.21593
doi: 10.1002/jso.21593
pubmed: 20740576
Su T-S, Liang P, Lu H-Z et al (2016) Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients. J Surg Oncol 113:181–187. https://doi.org/10.1002/jso.24128
doi: 10.1002/jso.24128
pubmed: 26799260
Takeda A, Sanuki N, Eriguchi T et al (2014) Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol 29:372–379. https://doi.org/10.1111/jgh.12350
doi: 10.1111/jgh.12350
pubmed: 23927053
van Leeuwen CM, Oei AL, Crezee J et al (2018) The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol 13:96. https://doi.org/10.1186/s13014-018-1040-z
doi: 10.1186/s13014-018-1040-z
pubmed: 29769103
pmcid: 5956964
Velec M, Haddad CR, Craig T et al (2017) Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 97:939–946. https://doi.org/10.1016/j.ijrobp.2017.01.221
doi: 10.1016/j.ijrobp.2017.01.221
pubmed: 28333016
Vogel A, Cervantes A, Chau I et al (2018) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:238–255. https://doi.org/10.1093/annonc/mdy308
doi: 10.1093/annonc/mdy308
Wahl DR, Stenmark MH, Tao Y et al (2016) Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 34:452–459. https://doi.org/10.1200/JCO.2015.61.4925
doi: 10.1200/JCO.2015.61.4925
pubmed: 26628466
Weiner AA, Olsen J, Ma D et al (2016) Stereotactic body radiotherapy for primary hepatic malignancies: report of a phase I/II institutional study. Radiother Oncol 121:79–85. https://doi.org/10.1016/j.radonc.2016.07.020
doi: 10.1016/j.radonc.2016.07.020
pubmed: 27566894
pmcid: 5543719
Xi M, Zhang L, Zhao L et al (2013) Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS ONE 8:e63864. https://doi.org/10.1371/journal.pone.0063864
doi: 10.1371/journal.pone.0063864
pubmed: 23737955
pmcid: 3667854
Yamashita H, Onishi H, Murakami N et al (2015) Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J Radiat Res 56:561–567. https://doi.org/10.1093/jrr/rru130
doi: 10.1093/jrr/rru130
pubmed: 25691453
pmcid: 4426924
Yoon SM, Lim Y-S, Park MJ et al (2013) Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS ONE 8:e79854. https://doi.org/10.1371/journal.pone.0079854
doi: 10.1371/journal.pone.0079854
pubmed: 24255719
pmcid: 3821847
Common Terminology Criteria for Adverse Events (CTCAE). 80